327
Participants
Start Date
November 30, 2008
Primary Completion Date
October 31, 2009
Study Completion Date
October 31, 2009
CP-690,550
Ophthalmic topical solution, low dose, dosed at least once/day, 8 weeks
CP-690,550
Ophthalmic topical solution, medium dose, dosed at least once/day, 8 weeks
CP-690,550
Ophthalmic topical solution, intermediate dose, dosed at least once/day, 8 weeks
CP-690,550
Ophthalmic topical solution, high dose, dosed at least once/day, 8 weeks
Cyclosporine
Ophthalmic topical solution, 0.05%, dosed at least once/day, 8 weeks
CP-690,550 Vehicle
Ophthalmic topical solution, dosed at least once/day, 8 weeks
Pfizer Investigational Site, Lynbrook
Pfizer Investigational Site, Rochester
Pfizer Investigational Site, Baltimore
Pfizer Investigational Site, High Point
Pfizer Investigational Site, Charlotte
Pfizer Investigational Site, Roswell
Pfizer Investigational Site, Morrow
Pfizer Investigational Site, Atlanta
Pfizer Investigational Site, Ormond Beach
Pfizer Investigational Site, Tamarac
Pfizer Investigational Site, Tampa
Pfizer Investigational Site, Stuart
Pfizer Investigational Site, Memphis
Pfizer Investigational Site, Louisville
Pfizer Investigational Site, Columbus
Pfizer Investigational Site, Cleveland
Pfizer Investigational Site, Kansas City
Pfizer Investigational Site, San Antonio
Pfizer Investigational Site, Austin
Pfizer Investigational Site, Austin
Pfizer Investigational Site, Austin
Pfizer Investigational Site, Centennial
Pfizer Investigational Site, Phoenix
Pfizer Investigational Site, Chandler
Pfizer Investigational Site, Peoria
Pfizer Investigational Site, Artesia
Pfizer Investigational Site, Boston
Lead Sponsor
Pfizer
INDUSTRY